AVIR Q2 2023 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$16M

Operating Income

-$35M

Net Income

-$28M

EPS (Diluted)

$-0.34

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$626M

Total Liabilities

$24M

Stockholders' Equity

$602M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$16M	$0	—
Operating Income	-$35M	-$32M	-9.1%
Net Income	-$28M	-$31M	+10.1%